dr. ou on alectinib as treatment for nsclc
Published 10 years ago • 819 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
2:45
dr. govindan on the potential for alectinib
-
3:59
alectinib in alk-mutated nsclc
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:27
dr. neal debates whether alectinib will become the standard frontline thera for alk nsclc
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
2:26
dr. shaw on alectinib as first-line therapy in lung cancer
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
7:13
alectinib for relapsed/refractory alk nsclc
-
2:32
dr. ou on investigational kras inhibitors in lung cancer
-
1:17
dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
-
1:39
key findings of the alex study: improved therapeutic options for alk-positive nsclc
-
1:12
dr. christina baik on alectinib in patients with alk-lung cancer
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
6:41
next-generation alk inhibitors for nsclc
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer